- Record: found
- Abstract: found
- Article: not found
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Daniel H Sterman
1 ,
Adri Recio ,
Richard G Carroll ,
Colin T Gillespie ,
Andrew Haas ,
Anil Vachani ,
Veena Kapoor ,
Jing Sun ,
Richard Hodinka ,
Jennifer L Brown ,
Michael J Corbley ,
Michael Parr ,
Mitchell Ho ,
Ira Pastan ,
Michael Machuzak ,
William Benedict ,
Xin-qiao Zhang ,
Elaina M Lord ,
Leslie A Litzky ,
Daniel F Heitjan ,
Carl H June ,
Larry R Kaiser ,
Robert H Vonderheide ,
Steven M Albelda ,
Michelle Kanther
Aug 01 2007
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
This phase 1 dose escalation study evaluated the safety and feasibility of single-dose intrapleural IFN-beta gene transfer using an adenoviral vector (Ad.IFN-beta) in patients with malignant pleural mesothelioma (MPM) and metastatic pleural effusions (MPE).